Electrovaya Receives Additional US$6.3 Million Order for Fortune 100 Customer — Neutral
ELVA Accesswire — June 03, 2025This purchase order is a follow on from other orders received during the fiscal year from the same end customer with a cumulative total over $16 million Further demands for additional sites expected later in the year TORONTO, ON / ACCESS Newswire / June 3, 2025 / Electrovaya Inc. ("Electrovaya" or the "Company") (NASDAQ:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced it has received purchase orders through its OEM sales channel valued at approximately US$6.3 million. The batteries will be used by a leading Fortune 100 e-commerce company in the United States for powering material handling electric …

OGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
OGN Accesswire — June 03, 2025NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Organon & Co. ("Organon" or "the Company") (NYSE:OGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Organon securities between October 31, 2024 and April 30, 2025, both dates inclusive (the "Class Period").

RCAT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Red Cat Holdings, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
RCAT Accesswire — June 03, 2025NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Red Cat Holdings, Inc. ("Red Cat" or "the Company") (NASDAQ:RCAT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Red Cat securities between March 18, 2022 and January 15, 2025, both dates inclusive (the "Class Period").

IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! — Neutral
IOVA Accesswire — June 03, 2025NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").

DNUT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Krispy Kreme, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! — Neutral
DNUT Accesswire — June 03, 2025NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Krispy Kreme, Inc. ("Krispy Kreme" or "the Company") (NASDAQ:DNUT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Krispy Kreme securities between February 25, 2025 and May 7, 2025, both dates inclusive (the "Class Period").

DV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DoubleVerify Holdings, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
DV Accesswire — June 03, 2025NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. ("DoubleVerify" or "the Company") (NYSE:DV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DoubleVerify securities between November 10, 2023 and February 27, 2025, both dates inclusive (the "Class Period").

MSTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MicroStrategy Incorporated d/b/a Strategy Shareholders Have Opportunity to Lead Class Action Lawsuit! — Neutral
MSTR Accesswire — June 03, 2025NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ("Strategy" or "the Company") (NASDAQ:MSTR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Strategy securities between April 30, 2024 and April 4, 2025, both dates inclusive (the "Class Period").

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
URGN Accesswire — June 03, 2025NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN) and certain of its officers.

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting — Neutral
BYSI GlobeNewsWire — June 03, 2025FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, on May 31st, 2025 in Chicago, IL.

QuantaSing to Report Third Fiscal Quarter Financial Results on June 6, 2025 — Neutral
QSG GlobeNewsWire — June 03, 2025BEIJING, June 03, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading lifestyle solution provider empowering adults to live better and longer, today announced that it plans to release its unaudited financial results for the quarter ended March 31, 2025, before the U.S. market opens on Friday, June 6, 2025.

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib — Neutral
TRAW GlobeNewsWire — June 03, 2025NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The paper, published in the British Journal of Dermatology 1 , details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated …

TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to provide an update on exploration plans for the Committee Bay project, located in the eastern Kitikmeot region of Nunavut, Canada. The 2025 Committee Bay exploration program will commence in early July 2025 and will comprise 7 – 10 diamond drill holes totaling approximately 5,000 metres (m).

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve — Neutral
FOLD GlobeNewsWire — June 03, 2025PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.

Swvl Signs Its First SaaS Contract in the UK, Marking Entry into the European Market — Neutral
SWVL GlobeNewsWire — June 03, 2025Swvl launches SaaS offering in the United Kingdom, securing its first enterprise contract and signaling the Company's strategic expansion into Europe

VEON and Engro Corporation Complete Pioneering Infrastructure Partnership in Pakistan — Neutral
VEON GlobeNewsWire — June 03, 2025Islamabad and Dubai, June 3, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or “the Company”), announces that it has successfully closed the partnership for the pooling and management of telecommunications infrastructure assets in Pakistan with Engro Corporation Limited (“Engro Corp”).

Proven Hits Return to Citytv & Citytv+; The Price is Right Tonight with Host Howie Mandel, Coming Spring 2026 — Neutral
RCI GlobeNewsWire — June 03, 2025– New Canadian original The Price is Right Tonight (working title) leads Citytv's audience-winning lineup built around strong franchises and the biggest special events –

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Neutral
BCRX GlobeNewsWire — June 03, 2025RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Brookfield Announces Reset Dividend Rate on Its Series 42 Preference Shares — Neutral
BN GlobeNewsWire — June 03, 2025All amounts in Canadian dollars unless otherwise stated. BROOKFIELD, NEWS, June 03, 2025 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has determined the fixed dividend rate on its Cumulative Class A Preference Shares, Series 42 (the “Series 42 Shares”) (TSX: BN.PF.G) for the five years commencing July 1, 2025 and ending June 30, 2030.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors — Neutral
BIIB TRDA GlobeNewsWire — June 03, 2025BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference — Neutral
SION GlobeNewsWire — June 03, 2025WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m.
